The UK Covid-19 Inquiry has announced that it has opened the Inquiry’s eighth investigation (Module 8) examining the impact of the Coronavirus (Covid-19) pandemic on children and young people. The Core Participant application window will be open from 21 May to 17 June 2024. The Inquiry has also announced that Module 9 will focus on the economic response to the Coronavirus pandemic. This investigation will open in July 2024. The Inquiry has also said that a further investigation is expected to be announced in the Autumn of 2024 which will explore the impact of the pandemic in various ways, including on the mental health and wellbeing of the population.

The Insolvency Service has reported that Charles Ling of Romford has received a 15-month suspended sentence for fraudulently obtaining a £30,000 coronavirus bounce back loan (BBL). Ling falsely claimed it was his first such loan, despite having already received a legitimate £20,000 loan, and having used £11,500 for personal expenses including cash withdrawals and mortgage payments. He was charged under sections 1 and 2 of the Fraud Act 2006, ordered to complete 100 hours of unpaid work, and has repaid the fraudulent loan. The case represents continued enforcement action against coronavirus support scheme misuse.

Coronavirus (COVID-19): Following the coronavirus (COVID-19) outbreak, some Companies House filing and other administrative procedures have been temporarily suspended or changed. For further details of the impact of COVID-19, see Practice Note: Coronavirus (COVID–19)—impact on company filing and administrative procedures [Archived]. A redenomination of share capital is the conversion of shares from having a fixed nominal value in one currency to having a fixed nominal value in another currency. Prior to 1 October 2009, a limited company having a share capital wanting to redenominate all or any of its share capital first had to cancel the shares by way of a reduction of capital or a share buyback (followed by a cancellation) before issuing new shares in the new currency. This process was administratively onerous, expensive and could have had potentially adverse tax consequences. On 1 October 2009, the Companies Act 2006 (CA 2006) introduced a new statutory regime for a redenomination of a company’s share capital or any class of its share capital. A redenomination of share capital may now be effected by way of a shareholders'

This Q&A has been drafted assuming the following: • the question is asked in the light of the ongoing coronavirus (COVID-19) crisis • the statutory declaration is intended to be administered prior to 30 September 2021 • the statutory declaration is one which falls within the scope of the Statutory Declarations Act 1835 • the statutory declaration is being administered in one of the following contexts: ◦ a company entering a members’ voluntary liquidation—section 89 of the Insolvency Act 1986 ◦ a company entering administration—the Insolvency (England and Wales) Rules 2016 (IR 2016), SI 2016/1024, r 3.17 Prior to the restrictions imposed by the government to tackle the spread of coronavirus, there was something of an unresolved debate concerning the question of whether a solicitor administering a statutory declaration was required to be physically present with the person giving the declaration. The

This week's edition of Insurance & Reinsurance weekly highlights includes: UK broker WTW launches Ukraine land war insurance cover; MPs mull using frozen Russian assets for Ukraine recovery; taxpayers could face bill for 'shadow fleet' oil spill; Coronavirus (COVID-19) business interruption—Disease clauses revisited (Bellini v Brit); Amtrust loses cap costs dispute in Lloyd’s syndicate deal (Premia Reinsurance Ltd v AmTrust International Insurance Ltd); Court of Appeal rules on exclusion in W&I policy (Project Angel Bidco v Axis); insurer beats engineering companies new bid for US$10m payout (Medgulf); Lloyd's tightens cyberwar insurance cover; the British Insurance Brokers' Association (BIBA) publishes two new guides on brokers’ commissions and premium finance; experts see risks in FCA's soft-touch response to AI; the European Insurance and Occupational Pensions Authority (EIOPA) publishes May 2024 Insurance Risk Dashboard; cases & decisions; key dates for your diary; and other news highlights reported over the past week.

Employment law dates for your 2022 diary This Practice Note is a summary of the key legal developments that impacted employment lawyers during the course of 2022. The tables below set out, in chronological order, dates of relevance for employment lawyers, covering cases, legislation and consultations, sorted by month during 2022. More information and links to relevant news stories can be found in: • Case tracker—Employment • Archived—2022 Case tracker—Employment • Legislation tracker—Employment • Coronavirus (COVID-19)—Legislation tracker for employment [Archived], and • Consultation tracker—Employment January 2022 Date Type of event Topic Subject 7 January 2022 (partly, and fully on 1 April 2022) Legislation in force Coronavirus (COVID-19)—vaccination The Health and Social Care Act 2008 (Regulated Activities) (Amendment) (Coronavirus) (No 2) Regulations 2022, SI 2022/15, amended the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014, SI 2014/2936, including to make further provision in relation to the vaccination of care home staff and entry into a care home 7 January 2022 (at 4.00 am partly, on 9 January 2022 at

This archived Practice Note is a summary of the key legal developments that are expected to impact corporate lawyers during 2021 and beyond. It is reviewed and updated throughout the year. Coronavirus (COVID-19) will continue to be a significant issue throughout 2021. In the first instance it may be useful to refer to the Coronavirus (COVID-19)—legislation tracker [Archived] and Practice Note: Coronavirus (COVID-19)—key issues for Corporate lawyers. Other key developments to look out for during 2021 will continue to include those connected to Brexit. To track Brexit-related legislation, including statutory instruments, see the Brexit legislation tracker [Archived]. It may also be useful to refer to the Brexit collection and Brexit timeline [Archived]. To track legal and regulatory developments relating to other specific topics, see: • Corporate governance horizon scanning—2021 and beyond • National Security and Investment Bill—progress tracker • National Security and Investment regime—market practice tracker [Archived] • UK listing and prospectus regime reform—progress tracker • SPAC tracker • Dual class share structure tracker • Listing Rules tracker • Prospectus Regulation Rules tracker • UK Prospectus Regulation tracker • EU

This week's edition of Public Law weekly highlights includes key public procurement updates, with the publication of the Draft Procurement Regulations 2024, the first suite of Procurement Act 2023 guidance documents and the government response to the consultation on Procurement Act 2023 draft implementing regulations. Additionally featured are selected Brexit headlines, including the first vote of the Northern Ireland Assembly whether an EU measure should apply under the Windsor Framework, and the latest Brexit SIs. This edition further includes updates on coronavirus (COVID-19); constitutional and administrative law; equality and human rights; judicial review; information law; subsidy control and State aid; and public procurement. Cases this week include analysis of a case which considered the compatibility of the routine redaction of the names of junior civil servants with the Duty of Candour, and examination of the Law Society’s judicial review of the Ministry of Justice’s criminal legal aid reforms implementation.

This week's edition of Public Law weekly highlights includes coverage of the Spring Statement 2025. Also in this edition, updates on the Cabinet Office’s call for written feedback for the Independent Review of the Windsor Framework, publication of the EU Finances Statement 2024 which reports that £25bn of the EU Withdrawal Agreement Financial Settlement has been paid, a new inquiry examining accessibility of parliamentary procedures, plus a Public Accounts Committee report examining artificial intelligence adoption across government. Case updates include a Court of Appeal decision quashing a prison Governor's refusal to submit an early release application, a decision partially granting a judicial review claim challenging a prisoner’s security categorisation review without an oral hearing, a decision granting an extension of time for a statutory appeal, plus a decision upholding refusal of an out-of-time homelessness review request. The highlights include further updates on Brexit SIs, Post-Brexit transition guidance, Coronavirus, constitutional and administrative law, equality and human rights, state security and intelligence, information law, subsidy control and State aid.

This week's edition of Insurance weekly highlights includes: racecourses lose early fight in £80m coronavirus (COVID-19) insurance dispute; AXA France IARD S.A. v Santander Cards UK Ltd; The Members of the Probitas Syndicate 1492 At Lloyd's for the 2022 Underwriting Year of Account v Pro 2 Care Ltd; Delos Shipholding S.A. v Allianz Global Corporate and Specialty S.E.; AXA wins £675m missold PPI payout dispute with Santander; European reinsurer fined £1.79m over post-brexit failings; Is the FCA’s cautious approach to insurance hurting UK consumers?; PRA finalises UK ISPV reforms with fast-track authorisation and updated prudential guidance; EIOPA publishes follow-up report on outsourcing under Solvency II plus dates for your diary and key recent cases.

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to amend the Medical Devices Regulations 2002, SI 2002/618 to incorporate common specifications for high-risk in vitro diagnostic (IVD) devices. The changes include repealing Coronavirus Test Device Approvals (CTDA) regulations and introducing an accelerated approval process for CE-marked Coronavirus Test Devices. This decision follows strong support from consultation respondents for replacing the CTDA process with the common specifications. The changes aim to ensure that IVD devices meet high performance standards supported by clinical evidence and improve patient care and public health outcomes.

ARCHIVED: This Practice Note has been archived and is not maintained. On 23 June 2016, the UK held a referendum on its membership of the EU, with a majority voting in favour of the UK leaving the EU. On 29 March 2017, the UK Prime Minister gave formal notification of the UK's intention to withdraw from the EU, commencing the withdrawal process under Article 50 TEU, see: Brexit: UK Article 50 TEU notification starts the clock—what happens now? On 31 January 2020, the UK’s formal withdrawal from the EU took effect and the UK ceased to be an EU Member State. Exit day marked the end of the withdrawal period under Article 50 TEU and the start of a time-limited transition/implementation period, during which the transitional arrangements provided in Part 4 of the Withdrawal Agreement applied. The transitional arrangements provided a standstill period during which the UK and EU worked to implement the Withdrawal Agreement and negotiate an agreement on the legal terms of their future relationship, to take effect after the implementation